#USA #New York #Pomerantz LLP #Investor Claims #Celcuity Inc.

Pomerantz Law Firm Investigates Claims Against Celcuity Inc.

On July 30, 2026, the renowned Pomerantz Law Firm announced it is thoroughly investigating claims on behalf of investors who hold shares in Celcuity Inc. (NASDAQ: CELC). The inquiry raises serious allegations surrounding the potential engagement in securities fraud by the company or specific officers and directors. Investors included in this probe are encouraged to reach out to attorney Danielle Peyton at Pomerantz for more information.

Background

Celcuity Inc., a biotech firm to watch, recently made headlines after obtaining U.S. Food and Drug Administration (FDA) approval for its innovative breast cancer therapy, Revtorpyk (gedatolisib). Announced on July 14, 2026, this news was significant for the company, as it anticipated a commercial launch by late Q3 2026. However, the projected launch date appears to be a setback compared to analysts' forecasts. Analysts like Stephen Wiley from Stifel noted the announcement of a Q3 2026 launch seemed prolonged, raising eyebrows regarding the operational readiness of Celcuity to bring this much-anticipated therapy to market.

The response from investors was swift and severe. Following the announcement, Celcuity's stock price plummeted by $19.54, translating to a sharp decrease of 17.6%, closing at $91.51 per share the next day.

The Role of Pomerantz LLP

Pomerantz LLP stands out in the legal field, especially known for its focus on corporate, securities, and antitrust class litigation. With a legacy of more than 85 years, the firm was founded by Abraham L. Pomerantz, a pioneer in the arena of securities class actions. Its reputation for successfully advocating for the rights of the victims of securities fraud, along with its ability to recover substantial damages on behalf of class members, makes it a formidable presence in class action lawsuits.

The firm takes pride in its rigorous investigation protocols, ensuring it can uncover potential wrongdoing effectively. This current investigation into Celcuity Inc. could indicate a broader concern regarding how companies communicate critical information and the impact of such disclosures on their stock performance.

Implications for Investors

For shareholders of Celcuity Inc., participation in this investigation could potentially provide a pathway towards recompense for financial losses. The firm is urging any investors who believe they may have been affected to join the action by contacting them directly. The ongoing investigation raises important questions about corporate governance and the legal obligations companies have towards their shareholders regarding accurate and timely communication.

Next Steps

Investors looking to participate or needing legal guidance should reach out to Pomerantz LLP. Details regarding joining the class action lawsuit are available through direct contact with Danielle Peyton. Investors have a crucial role to play in holding firms accountable for their actions, especially in matters of substantial financial significance like this.

As this situation develops, it highlights the importance of diligent oversight in the biotech sector, where stakes are high, and the potential consequences of corporate decision-making can reverberate through the market. The upcoming months will shed light on whether Celcuity can recover from this setback and what protections investors can expect moving forward.

For more information and updates on this case, continue following relevant press releases and news updates from Pomerantz LLP.